Cargando…
Lefamulin, a recently approved novel antibacterial agent to fight against community-acquired bacterial pneumonia
Autores principales: | Choudhury, Shouvik, Bala, Moumita, Chakraborty, Dwaipayan Sarathi, Lahiry, Sandeep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194436/ https://www.ncbi.nlm.nih.gov/pubmed/33942766 http://dx.doi.org/10.4103/lungindia.lungindia_93_20 |
Ejemplares similares
-
Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia
por: Sarathi Chakraborty, Dwaipayan, et al.
Publicado: (2023) -
Osimertinib as an emerging therapeutic modality in nonsmall cell lung cancer: Opportunities and challenges in Indian scenario
por: Thakur, Sayanta, et al.
Publicado: (2020) -
Past, Present, and Future of Remdesivir: An Overview of the Antiviral in Recent Times
por: Choudhury, Shouvik, et al.
Publicado: (2020) -
Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia
por: Tang, Hung-Jen, et al.
Publicado: (2020) -
Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin
por: Eraikhuemen, Nathaniel, et al.
Publicado: (2021)